Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 10/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14226902 | 0.84 | ALDH1A1 (0.60) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL14226835 | 0.82 | MAPT (0.56) | SMN1; SMN2GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL11102795 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL17478873 | 0.81 | GAA (0.65) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL3928569 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL17478643 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL17559747 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL2855312 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL17177050 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL19680521 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2GAAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | SMN1; SMN2 3532/4885GAA 1245/4885KDM4E 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.